论文部分内容阅读
目的观察西格列汀单用与联合阿卡波糖对初诊2型糖尿病(T2DM)患者的疗效。方法将60例初诊T2DM患者随机分成西格列汀单药治疗组(单药组)及西格列汀联合阿卡波糖治疗组(联合组),每组各30例。在饮食控制的基础上治疗12周,比较两组治疗前后体重指数(BMI)、空腹血糖(FBG)、餐后2-h血糖(2-hPG)、糖化血红蛋白(HbA1c)、三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、空腹胰岛素(FIns)及胰岛素抵抗指数(HOMA-IR)。结果经12周治疗,两组BMI、FBG、2-hPG、HbA1c、TG、FIns和HOMA-IR较治疗前下降(P<0.05);TC、LDL-C差异无统计学意义(P>0.05)。联合组FBG、2-hPG、HbA1c及HOMA-IR较单药组下降更明显(P<0.05)。结论西格列汀联合阿卡波糖治疗初诊T2DM具有较好的疗效。
Objective To observe the effect of sitagliptin alone and combined with acarbose on newly diagnosed type 2 diabetes mellitus (T2DM). Methods Sixty newly diagnosed T2DM patients were randomly divided into sitagliptin monotherapy group (single drug group) and sitagliptin combined with acarbose treatment group (combination group), 30 cases in each group. BMI, fasting blood glucose (FBG), postprandial 2-h blood glucose (2-hPG), glycosylated hemoglobin (HbA1c), triglyceride (TG) ), Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), fasting insulin (FIns) and insulin resistance index (HOMA-IR). Results After 12 weeks treatment, the levels of BMI, FBG, 2-hPG, HbA1c, TG, FIns and HOMA-IR in the two groups were significantly lower than those before treatment (P 0.05) . FBG, 2-hPG, HbA1c and HOMA-IR decreased more significantly in the combination group than in the single drug group (P <0.05). Conclusion Sedrin and acarbose treatment of newly diagnosed T2DM has a good effect.